Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$9,036 Mln
P/E Ratio
--
P/B Ratio
0.48
Industry P/E
--
Debt to Equity
0.86
ROE
-0.03 %
ROCE
-1.73 %
Div. Yield
6.34 %
Book Value
15.61
EPS
-0.53
CFO
$21,281.60 Mln
EBITDA
$17,210.40 Mln
Net Profit
$3,516.60 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Viatris (VTRS)
| -38.23 | -15.96 | -32.13 | -31.64 | -10.29 | -12.66 | -20.27 |
|
BSE Sensex*
| 2.27 | 4.06 | 4.74 | 8.66 | 11.85 | 20.59 | 11.12 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Viatris (VTRS)
| 14.83 | -2.70 | -17.74 | -27.80 | -6.77 | -26.64 | -35.09 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 61.50 | 11,346.08 | 26.54 | 8.05 | |
| 34.18 | 6,373.23 | -- | 38.11 | |
| 64.68 | 6,636.14 | 51.14 | 23.56 | |
| 57.38 | 11,265.03 | 378.67 | 0.76 |
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments:... Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Address: Robert J. Coury Global Center, Canonsburg, PA, United States, 15317 Read more
CEO & Director
Mr. Scott Andrew Smith
CEO & Director
Mr. Scott Andrew Smith Ph.D.
Headquarters
Canonsburg, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Viatris Inc (VTRS) stood at $ 41,501 Mln as on 31-Dec-24
The share price of Viatris Inc (VTRS) is $7.69 (NASDAQ) as of 22-Apr-2025 16:00 EDT. Viatris Inc (VTRS) has given a return of -10.29% in the last 3 years.
Viatris Inc (VTRS) has a market capitalisation of $ 9,036 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Viatris Inc (VTRS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Viatris Inc (VTRS) and enter the required number of quantities and click on buy to purchase the shares of Viatris Inc (VTRS).
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Address: Robert J. Coury Global Center, Canonsburg, PA, United States, 15317
The CEO & director of Mr. Scott Andrew Smith. is Viatris Inc (VTRS), and CFO & Sr. VP is Mr. Scott Andrew Smith Ph.D..
There is no promoter pledging in Viatris Inc (VTRS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,131
|
|
|
1,128
|
|
|
682
|
|
|
644
|
| Viatris Inc. (VTRS) | Ratios |
|---|---|
|
Return on equity(%)
|
-3.24
|
|
Operating margin(%)
|
-0.5
|
|
Net Margin(%)
|
-4.3
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Viatris Inc (VTRS) was $-634 Mln.
$0.12
(
